The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation-Reference-Cited by-同舟云学术

The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation

Published:2018-12-01 Issue:4 Volume:21 Page:572-580
ISSN:1099-5129
Container-title:EP Europace
language:en
Short-container-title:

Author:

Vinding Naja Emborg¹,Bonde Anders Nissen²,Rørth Rasmus¹,Lamberts Morten¹²,Olesen Jonas Bjerring²,Gislason Gunnar Hilmar²³⁴,Torp-Pedersen Christian⁵⁶,Køber Lars¹,Fosbøl Emil Loldrup¹

Affiliation:

1. Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 3, København Ø, Denmark

2. Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte, Kildegaardsvej 28, Hellerup, Denmark

3. The Danish Heart Foundation, Vognmagergade 7, Copenhagen, Denmark

4. The National Institute of Public Health, University of Southern Denmark, Øster Farimagsgade 5A, Copenhagen, Denmark

5. Institute of Health, Science and Technology, Aalborg University, Niels Jernes Vej 12, Aalborg Ø, Denmark

6. Aalborg University Hospital, Unit of Epidemiology and Biostatistics, Aalborg, Denmark

Funder

Department of Cardiology

Copenhagen University Hospital

Bayer, and Boehringer Ingelheim

The Capital Region of Denmark Foundation for Health Research

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/europace/article-pdf/21/4/572/28279284/euy262.pdf

Reference20 articles.

1. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS;Kirchhof;Europace,2016

2. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V;White;Arch Intern Med,2007

3. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

4. Rivoroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

5. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial;Wallentin;Lancet,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review;BMJ Open;2023-04

2. The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials;Therapeutics and Clinical Risk Management;2023-03

3. Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation;European Journal of Clinical Pharmacology;2023-01-28

4. A retrospective cohort study of pharmacogenetics of warfarin dosing in Chinese Adults with nonvalvular atrial fibrillation;2022-10-19

5. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation;Journal of the American Heart Association;2022-02-15